With a host of biologic products in its pipeline, Bristol-Myers Squibb sees the need for more capacity for making large-molecule drugs and has decided to build on a relationship it already has with South Korea's Samsung BioLogics.
It's been almost a yearlong contest, but a deal for patchmaker LTS Lohmann appears to be nearing the finish line. The private equity firm Nordic Capital is likely to beat out competitor Wendel for the deal, Bloomberg says, at a price of about $1.7 billion.
A strong regulatory agency and the patient confidence it inspires are essential for both patients and the industry as a whole, Sanofi CEO Chris Viehbacher said Thursday. And while the FDA has made recent strides in restoring the patient trust the agency depends on, Commissioner Margaret Hamburg says it still has some work to do.
Eli Lilly has been combatting counterfeiters for more than 10 years, but now, the drugmaker has decided it's time to up its efforts. It's latest move: Investing $110 million into stamping unique codes and serial numbers on every drug package it sells worldwide, making them trackable--and hopefully stumping crafty counterfeiters in the process.
GlaxoSmithKline has its second recall in as many weeks on its hands, this time affecting batches of the antidepressant Paxil that contain an ingredient manufactured at an Irish plant the FDA says isn't up to snuff.
Lots of drugmakers see Africa as a market that over time can produce some substantial business. But GlaxoSmithKline is not just manufacturing and selling drugs there. It is going one better with a new "open lab" R&D facility to let African researchers work on the drugs needed by Africans for noncommunicable diseases.
Regeneron will continue forth with its €220 million plans to revamp a former Dell plant in Ireland now that an interest group has pulled its appeal, making room to flesh out its product line beyond blazing eye treatment Eylea.
Johnson & Johnson's Janssen, which has struggled to maintain ready supplies of its ovarian cancer treatment Doxil, has released a new lot of the popular drug. The injectable cancer med was produced through an "alternative manufacturing approach" in which the now-closed Ben Venue plant in Ohio made the bulk product and another manufacturer finished it off.
How do you halve the time it takes for GlaxoSmithKline toothpaste makers to change over their lines? Reenvision the production line as an F1 racetrack, according to McLaren.
India's Cipla has been aggressive about taking aim at Western meds it thinks are too expensive for the Indian market, sometimes targeting those that have seen their patents pushed aside by compulsory licenses. But drugmaker Merck has a new deal with Cipla that might help it sidestep that issue.